PubMed
Cagrilintide, a long-acting amylin analogue, for the treatment of obesity
Lau DCW, Erondu N, Skovgaard D, et al. Lancet. 2022
Compare
Cagrilintide vs LL-37
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
Cagrilintide
29 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 98% · Mixed 2% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
139
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
1
Digestive upset
1
Injection site irritation
1
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 0 to ≥ 2 mg (open-ended top bucket)
0–0.025 mg
41
0.2–0.4 mg
9
0.4–0.6 mg
2
0.6–1 mg
3
1–2 mg
1
2+ mg
83
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 87% said they felt similar to their last entry, 13% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 142 days · Based on 23 repeat reporters
LL-37
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 100% · Mixed 0% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
6
Self-reported dose per injection
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 100–400 mcg
100–200
4
200–400
2
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Sources (9)
Published sources linked on the Cagrilintide and LL-37 wiki pages.
- Wiki study page →Source
- Wiki study page →Source
ClinicalTrials.gov
Cagrilintide obesity studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
D'Ascanio AM, Mullally JA, Frishman WH. Cardiology in review. 2024
- Wiki study page →Source
PubMed
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Garvey WT, Blüher M, Osorto Contreras CK, et al. The New England journal of medicine. 2025
- Wiki study page →Source
PubMed
LL-37, the only human member of the cathelicidin family of antimicrobial peptides
Vandamme D, Landuyt B, Luyten W, et al. Biochim Biophys Acta. 2012
- Wiki study page →Source
PubMed
The antimicrobial peptide LL-37 inhibits biofilm formation
Dean SN, Bishop BM, van Hoek ML. BMC Microbiol. 2011
- Wiki study page →Source
ClinicalTrials.gov
LL-37 studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Rosacea: Pathogenesis and Therapeutic Correlates
Geng RSQ, Bourkas AN, Mufti A, et al. Journal of cutaneous medicine and surgery. 2024
- Wiki study page →Source
PubMed
LL-37 antimicrobial peptide: Molecular characterisation and its role in oral health and disease-A narrative review
Soman D, P J, Cm M, et al. Archives of oral biology. 2026